At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
APL-2drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)
In Brief
A Phase 2 clinical trial evaluating APL-2 for IgA Nephropathy and 4 related conditions. Completed, enrolled 21 participants across 17 sites.
Detailed Summary
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartFeb 2018
First PostedMar 2018
Primary CompletionApr 2020
Study CompletionAug 2023
TodayJul 2026
First PostedMar 5, 2018
Enrollment StartFeb 26, 2018
Primary CompletionApr 16, 2020
Study CompletionAug 26, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.3 years ago
Interventions
APL-2drug
APL-2 administered as a daily subcutaneous infusion for 48 weeks